Study

EORTC-40071

Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial.

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 09-Dec-2010
Date Step1 close: 09-Aug-2013

Data management at EORTC

Yes

Design

Phase 2
Randomized blind

Targeted Sample size

EORTC Groups: 192 - All Groups: 192

Protocol summary

http://clinicaltrials.gov/study/NCT01123473

NCT number

NCT01123473

EudraCT

2009-011580-36